Overview

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.

Phase:

Phase 4

Details

Lead Sponsor:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Collaborator:

Progenics Pharmaceuticals, Inc.

Treatments:

Analgesics, Opioid
Bromides
Methylnaltrexone
Naltrexone